tetano
Editor, Senior Moderator
ESMO Open
. 2022 Feb 10;7(2):100423.
doi: 10.1016/j.esmoop.2022.100423. Online ahead of print.
Outcomes of patients with cancer infected with SARS-CoV-2: results from the Ion Chiricuţă Oncology Institute series
A Preda[SUP] 1 [/SUP], T Ciuleanu[SUP] 1 [/SUP], P Kubelac[SUP] 2 [/SUP], N Todor[SUP] 3 [/SUP], O Balacescu[SUP] 3 [/SUP], P Achimas-Cadariu[SUP] 1 [/SUP], D Iancu[SUP] 3 [/SUP], C Mocan[SUP] 3 [/SUP], M Bandi-Vasilica[SUP] 3 [/SUP], M Lupse[SUP] 4 [/SUP], V T Briciu[SUP] 5 [/SUP], M A Man[SUP] 6 [/SUP], C Vlad[SUP] 1 [/SUP]
Affiliations
Abstract
Background: The evolution of COVID-19 is a controversial topic in cancer patients. They have been designated by international organizations as a vulnerable population at greater risk for contracting SARS-CoV-2 and having a more severe clinical outcome.
Patients and methods: Active screening at our institution became routine early in the pandemic. We have examined the clinical data of 341 cancer patients, with a positive RT-PCR SARS-CoV-2 test between April 2020 and February 2021, in the prevaccination era.
Results: During the infection, 40.5% remained asymptomatic, 27.6% developed a mild form, 20.5% had a moderate form, and 11.4% a severe/critical form of COVID-19 that led to death in 7.6% of cases. Treatment was adapted to disease severity according to national guidelines. In our series, the incidence of COVID-19 infection was lower in cancer patients compared with the general population (P < 0.001), however, the mortality rate was higher in cancer patients in comparison with the general population (7.6% versus 2.9%, P < 0.001). The prognostic factors were assessed by three distinct univariate and multivariate analyses: (i) evolution to a moderate or severe/critical clinical manifestation, (ii) clinical worsening (severe/critical form or death), and (iii) overall survival. In the multivariate analysis, the prognostic factors associated with the evolution to a moderate or severe/critical clinical manifestation were: performance status (PS) (P < 0.0001) and no active treatment in the previous 3 months (P = 0.031). Factors associated with clinical worsening were: PS (P < 0.0001), peripheral arterial disease (P = 0.03), and chronic liver disease (P = 0.04). Factors associated with impaired overall survival were PS (P < 0.0001), ischemic cardiac disease (P = 0.0126), chronic liver disease (P = 0.001), and radiotherapy (P = 0.0027).
Conclusion: Our series confirms a more severe evolution for COVID-19 infection in cancer patients, with PS as the most prominent prognostic factor in all three multivariate analyses. By active screening, efforts should be in place to keep cancer units as coronavirus-free sanctuaries.
Keywords: COVID-19 pandemic; cancer; prognostic factors.
. 2022 Feb 10;7(2):100423.
doi: 10.1016/j.esmoop.2022.100423. Online ahead of print.
Outcomes of patients with cancer infected with SARS-CoV-2: results from the Ion Chiricuţă Oncology Institute series
A Preda[SUP] 1 [/SUP], T Ciuleanu[SUP] 1 [/SUP], P Kubelac[SUP] 2 [/SUP], N Todor[SUP] 3 [/SUP], O Balacescu[SUP] 3 [/SUP], P Achimas-Cadariu[SUP] 1 [/SUP], D Iancu[SUP] 3 [/SUP], C Mocan[SUP] 3 [/SUP], M Bandi-Vasilica[SUP] 3 [/SUP], M Lupse[SUP] 4 [/SUP], V T Briciu[SUP] 5 [/SUP], M A Man[SUP] 6 [/SUP], C Vlad[SUP] 1 [/SUP]
Affiliations
- PMID: 35279526
- DOI: 10.1016/j.esmoop.2022.100423
Abstract
Background: The evolution of COVID-19 is a controversial topic in cancer patients. They have been designated by international organizations as a vulnerable population at greater risk for contracting SARS-CoV-2 and having a more severe clinical outcome.
Patients and methods: Active screening at our institution became routine early in the pandemic. We have examined the clinical data of 341 cancer patients, with a positive RT-PCR SARS-CoV-2 test between April 2020 and February 2021, in the prevaccination era.
Results: During the infection, 40.5% remained asymptomatic, 27.6% developed a mild form, 20.5% had a moderate form, and 11.4% a severe/critical form of COVID-19 that led to death in 7.6% of cases. Treatment was adapted to disease severity according to national guidelines. In our series, the incidence of COVID-19 infection was lower in cancer patients compared with the general population (P < 0.001), however, the mortality rate was higher in cancer patients in comparison with the general population (7.6% versus 2.9%, P < 0.001). The prognostic factors were assessed by three distinct univariate and multivariate analyses: (i) evolution to a moderate or severe/critical clinical manifestation, (ii) clinical worsening (severe/critical form or death), and (iii) overall survival. In the multivariate analysis, the prognostic factors associated with the evolution to a moderate or severe/critical clinical manifestation were: performance status (PS) (P < 0.0001) and no active treatment in the previous 3 months (P = 0.031). Factors associated with clinical worsening were: PS (P < 0.0001), peripheral arterial disease (P = 0.03), and chronic liver disease (P = 0.04). Factors associated with impaired overall survival were PS (P < 0.0001), ischemic cardiac disease (P = 0.0126), chronic liver disease (P = 0.001), and radiotherapy (P = 0.0027).
Conclusion: Our series confirms a more severe evolution for COVID-19 infection in cancer patients, with PS as the most prominent prognostic factor in all three multivariate analyses. By active screening, efforts should be in place to keep cancer units as coronavirus-free sanctuaries.
Keywords: COVID-19 pandemic; cancer; prognostic factors.